Sana Biotechnology's proposed treatment for lupus, SC291, has received fast track designation from the FDA. Developed using Sana's hypoimmune platform, the CD19-directed allogeneic CAR T cell therapy is being evaluated in a trial for B-cell mediated autoimmune diseases.